Enapotamab vedotin
Enapotamab vedotin is an AXL-targeted antibody-drug conjugate (ADC) with inhibitory potential against high AXL expressing non-small cell lung cancer (NSCLC). Enapotamab vedotin also exhibits resistant to EGFR inhibitor such as Osimertinib (HY-15772).
For research use only. We do not sell to patients.
- CAS No.: 1912424-97-5
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
AXL[1]
Enapotamab vedotin (0-10 μg/mL, 5 days) exhibits cytotoxicity in cells with high AXL expression such as ER20 and H1975-OR2, and reduces the cell viability[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:ER20, H1975-OR2
-
Concentration:0-10 μg/mL
-
Incubation Time:5 days
-
Result:Reduced the cell viability.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:LU0395 xenograft mouse models[1]
-
Dosage:2-4 mg/kg
-
Administration:iv, once weekly for 2 doses
-
Result:Inhibited the tumor growth.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1912424-97-5
-
SMILES
[Enapotamab vedotin]
-
Synonyms
HuMax-AXL-ADC
-
Shipping
Shipping with dry ice.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Enapotamab vedotin Related Classifications
HY-P99921 Related Classifications
Powered by Bioz